GlassScriptPhysician profile
Bahram Eslami
NPI 1033112313
$3,547.26
in general payments reported to CMS, 2019-2025
27 companies · $704 in 2025
The $704 reported for 2025 was more than what 84% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $505 · 2020: $101 · 2021: $286 · 2022: $888 · 2023: $483 · 2024: $580 · 2025: $704.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,766.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $489.28 | 2022-2024 | Corevalve Evolut R, Linq II |
| Novartis Pharmaceuticals Corporation | $365.55 | 2020-2025 | |
| Pfizer INC. | $306.59 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $256.78 | 2021-2025 | Verquvo |
| Astellas Pharma US INC | $243.77 | 2019-2020 | |
| Amgen INC. | $227.47 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $218.45 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $216.79 | 2022-2025 | Ozempic, Wegovy |
| Medtronic Vascular, INC. | $185.00 | 2019 | |
| Biotronik INC. | $165.35 | 2020-2025 | |
| Janssen Pharmaceuticals, INC | $141.89 | 2020-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $102.18 | 2023-2024 | Jardiance |
| Abbott Laboratories | $88.72 | 2021-2023 | Cardiomems |
| Astrazeneca Pharmaceuticals LP | $76.50 | 2022-2025 | Farxiga, Wainua |
| Boston Scientific Corporation | $67.66 | 2019-2024 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $61.19 | 2024 | Arcalyst |
| Abiomed | $47.36 | 2024 | Impella |
| Otsuka America Pharmaceutical, INC. | $46.08 | 2019 | |
| Lilly USA, LLC | $44.14 | 2025 | Mounjaro, Zepbound |
| Kestra Medical Technology Services, INC. | $38.84 | 2022-2024 | Assure Wcd |
| Impulse Dynamics (USA) INC. | $34.12 | 2023 | Optimizer |
| Livanova USA, INC. | $27.26 | 2025 | Xtra |
| Bayer Healthcare Pharmaceuticals INC. | $21.07 | 2025 | |
| Scpharmaceuticals INC. | $20.23 | 2025 | |
| Cleerly, INC. | $20.17 | 2025 | Cleerly Labs, Cleerly Ischemia |
| Actelion Pharmaceuticals US, INC. | $18.57 | 2019 | |
| Bsn Medical INC | $16.25 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bahram Eslami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.